Literature DB >> 26518568

Is it possible to define early distal cholangiocarcinoma?

Fumihiko Miura1, Keiji Sano2, Hodaka Amano2, Naoyuki Toyota2, Keita Wada2, Takuo Tokairin3, Fukuo Kondo3, Koichi Hayano4, Hisahiro Matsubara4, Tadahiro Takada2.   

Abstract

PURPOSE: The feasibility of defining early cholangiocarcinoma has not been adequately evaluated. The surgical outcomes of patients who had undergone pancreatoduodenectomy (PD) for pathological T1 (pT1) distal cholangiocarcinoma (DCC) were evaluated to determine whether it is possible to define early DCC.
METHODS: The clinicopathological data of 18 patients with pT1 DCC who had undergone PD were reviewed retrospectively. Depth of fibromuscular (fm) layer invasion was divided into two categories: fm1 and fm2 (without adventitia fascia invasion and with adventitia fascia invasion). Comparative analyses were performed according to the depth of invasion.
RESULTS: Disease-specific survival rates of patients with five mucosal tumors and 13 fm-invasive tumors were 80 and 61.9 % at 5 years and 80 and 41.2 % at 10 years, respectively. There was no significant difference in disease-specific survival rates between the two groups (P = 0.244). Disease-specific survival rates of patients with 7 fm1-invasive tumors and 6 fm2-invasive tumors were 85.7 and 40 % at 5 years and 85.7 and 0 % at 10 years. A significant difference in disease-specific survival rates was observed between mucosal tumors and fm2-invasive tumors (P = 0.043), and disease-specific survival rates of mucosal tumors and fm1-invasive tumors were similar (P = 0.968).
CONCLUSIONS: Defining early DCC as carcinoma confined to the fm of the bile duct might be inappropriate; early DCC should be limited to the mucosal carcinoma.

Entities:  

Keywords:  Distal cholangiocarcinoma; Early cancer

Mesh:

Year:  2015        PMID: 26518568     DOI: 10.1007/s00423-015-1351-6

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  28 in total

1.  Reconsideration of the histologic definitions used in the pathologic staging of extrahepatic bile duct carcinoma.

Authors:  Seung-Mo Hong; Alison E Presley; Edward B Stelow; Henry F Frierson; Christopher A Moskaluk
Journal:  Am J Surg Pathol       Date:  2006-06       Impact factor: 6.394

2.  Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome.

Authors:  Manousos M Konstadoulakis; Sasan Roayaie; Ilias P Gomatos; Daniel Labow; Maria-Isabell Fiel; Charles M Miller; Myron E Schwartz
Journal:  Surgery       Date:  2007-12-21       Impact factor: 3.982

3.  Early cancer of the stomach.

Authors:  T Murakami
Journal:  World J Surg       Date:  1979-11       Impact factor: 3.352

4.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

5.  Clinicopathological review of 61 patients with early bile duct cancer.

Authors:  J M Cha; M H Kim; S K Lee; D W Seo; S S Lee; J H Lee; S G Lee; S J Jang
Journal:  Clin Oncol (R Coll Radiol)       Date:  2006-11       Impact factor: 4.126

6.  Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Akira Nakashima; Naru Kondo; Ryutaro Sakabe; Hiroki Ohge; Taijiro Sueda
Journal:  Ann Surg Oncol       Date:  2010-10-14       Impact factor: 5.344

7.  Depth of invasion determines the postresectional prognosis for patients with T1 extrahepatic cholangiocarcinoma.

Authors:  Masayuki Nagahashi; Yoshio Shirai; Toshifumi Wakai; Jun Sakata; Yoichi Ajioka; Tatsuya Nomura; Yoshiaki Tsuchiya; Katsuyoshi Hatakeyama
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

8.  Changing international trends in mortality rates for liver, biliary and pancreatic tumours.

Authors:  Shahid A Khan; Simon D Taylor-Robinson; Mireille B Toledano; Angus Beck; Paul Elliott; Howard C Thomas
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

9.  Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience.

Authors:  Sung Gyu Lee; Gi Won Song; Shin Hwang; Tae Yong Ha; Deok Bog Moon; Dong Hwan Jung; Ki Hun Kim; Chul Soo Ahn; Myung Hwan Kim; Sung Koo Lee; Kyu Bo Sung; Gi Young Ko
Journal:  J Hepatobiliary Pancreat Sci       Date:  2009-10-23       Impact factor: 7.027

10.  Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.

Authors:  T Okusaka; K Nakachi; A Fukutomi; N Mizuno; S Ohkawa; A Funakoshi; M Nagino; S Kondo; S Nagaoka; J Funai; M Koshiji; Y Nambu; J Furuse; M Miyazaki; Y Nimura
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.